Tous Actualités
Suivre
Abonner LifeWatch AG

LifeWatch AG

EANS-Adhoc: LifeWatch AG
Fourth Quarter 2012 and Full Fiscal Year 2012 Results confirm successful turnaround (with document)

2 Documents

--------------------------------------------------------------------------------
  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
--------------------------------------------------------------------------------
Annual Reports/annual report
26.02.2013


- EBIT of USD 0.65 million and EBITDA of USD 1.57 million in Q4 2012

- Net profit of USD 0.47 million in Q4 2012

- Reduction of total departmental expenses of USD 10.4 million in FFY 2012

- Additional 138 new or amended contracts for ACT and HST, respectively

International analyst and media conference and audio web cast on LifeWatch Q4
2012 and full fiscal year 2012 results

- Tuesday, February 26, 2013 at 10.00 a.m. CET

- Dial-in number: + 41 (0)91 610 56 00 (Europe), + 44 (0)203 059 58 62 (UK),
  +1 (1)866 291 41 66 (USA - Toll-free)

- Audio web cast http://services.choruscall.eu/links/lifewatch130226.html


Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE),
the leading provider of wireless telemedicine, today announces the results for
the fourth quarter 2012 and full fiscal year 2012. The Company continues in the
fourth quarter 2012 to present an operating profit on EBIT and EBITDA level and
as well as a net profit. Total department expenses for full fiscal year 2012
were reduced by over USD 10 million. Furthermore LifeWatch succeeded in 2012 in
closing 138 new or amended contracts for its ACT services and Home Sleep
Testing, respectively.

You will find a PDF-version of this press release and of the letter to
shareholders with the results of Q4 2012 and full fiscal year 2012 at the end
of this message.


Fourth Quarter 2012 Financial Highlights:


- Revenues of USD 20.07 million compared with USD 22.24 million in Q4 2011


- Gross margin of 56.6% compared with 60.6% in Q4 2011


- Total departmental expenses were 53.4% of revenues compared with 60.2% in
  Q4 2011


- EBIT of USD 0.65 million compared with EBIT of USD 0.09 million in Q4 2011


- EBITDA of USD 1.57 million compared with EBITDA of USD 1.08 million in Q4
  2011


- Net profit of USD 0.47 million compared with net loss of USD 0.55 million
  in Q4 2011


Full Fiscal Year 2012 Financial Highlights:

- Revenues of USD 80.11 million compared with USD 82.24 million in FFY 2011


- Operating costs were USD 10.4 million less than in FFY 2011


- EBIT and EBITDA of USD 4.17 million and USD 8.15 million compared with
  LBIT and LBITDA of USD 28.22 million and USD 22.92 million respectively in
  FFY 2011


- Net loss of USD 0.37 million compared with a net loss of USD 31.97 million
  in FFY 2011


- Delayed Medicare payment of approximately USD 3.5 million impacted cash,
  cash equivalents, marketable securities and structures, which were USD
  5.95 million on December 31, 2012


Revenues

During the course of FFY 2012 the Company saw a rise in patients who declined
their monitoring service prescribed by their physician. This situation is
impacting healthcare delivery across the USA, and we discussed it in the Letter
to Shareholders. These trends underscore our strategy of diversifying into new
territories and with new monitoring platforms for other disease states.

Quarterly: Revenues for Q4 of 2012 reached USD 20.07 million, a decline of
almost 10% over Q4 2011 revenues of USD 22.24 million, yet an increase of
approx. 1% over Q3 2012 revenues.

Annually: Revenues for FFY 2012 reached USD 80.11 million, which reflects a
decrease of approximately 2.6% from FFY 2011 revenues of USD 82.24 million.


Gross Profit, EBIT and EBITDA

Fourth Quarter 2012:

- Gross profit during this reporting quarter reached USD 11.36 million with
  a margin of 56.6% compared with a gross profit of USD 13.48 million and a
  margin of 60.6% in Q4 2011. Gross margin was impacted by the decrease in
  Q4 2012 revenues.

- EBIT this quarter was USD 0.65 million with a margin of 3.2% compared with
  Q4 2011 EBIT of USD 0.09 million and a margin of 0.4%.

- EBITDA this quarter reached USD 1.57 million with a margin of 7.8%
  compared with EBITDA of USD 1.08 million and a margin of 4.9% in Q4 2011.


Full Fiscal Year 2012:

- Gross profit in FFY 2012 reached USD 45.93 million with a margin of 57.3%
  compared with FFY 2011 gross profit of USD 43.44 million with a margin of
  52.8%. The cost cutting measures, including a reduction of headcount and
  decrease in depreciation expenses were the main reasons for the positive
  impact on 2012 FFY gross profit margin.

- EBIT in FFY 2012 was USD 4.17 million with a margin of 5.2% compared with
  LBIT of USD 28.22 million for FFY 2011.


Net Income/Loss

Fourth Quarter 2012: Net income for this quarter was USD 0.47 million with a
margin of 2.3% compared with a net loss of USD 0.55 million in Q4 2011. Fully-
diluted earnings per share were USD 0.03 this quarter compared with a fully-
diluted loss per share of USD 0.04 in Q4 2011.

Full Fiscal Year 2012: Net loss for FFY 2012 was USD 0.37 million compared with
a net loss of USD 31.97 million in FFY 2011. Fully-diluted loss per share was
USD 0.03 in FFY 2012 compared with fully-diluted loss per share of USD 2.56 in
FFY 2011.


Outlook 2013

LifeWatch executed a successful turnaround and returned to operational
profitability in 2012. Nonetheless, reimbursement in the U.S. remains a
challenge. Despite the increased competition in cardiac monitoring services,
LifeWatch will focus on strengthening its position through additional market
share in the cardiac and home sleep testing market, expansion of sales and
marketing efforts in large metropolitan areas, and the introduction of new
programs for monitoring other disease conditions. Our LifeWatch V business
development team is intensely focused on identifying growth opportunities and
strategic partnerships in new markets, and has identified a number of strategic
partnerships to pursue in 2013. Our long-term growth strategy of product and
geographical diversification looks promising.

For further information please contact:

Sensus Communication Consultants, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email  lifewatch@sensus.ch

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote patient
monitoring services. LifeWatch services cater to individuals, ranging from
high-risk and chronically ill patients, to consumers of health and wellness
products. LifeWatch AG has operative subsidiaries in the United
States, in Switzerland and in Israel and is the parent company of LifeWatch
Services Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a
leading US-based provider of cardiac monitoring services and home sleep testing
of Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel,
is a leading developer and manufacturer of telemedicine products. The Company is
planning to introduce the LifeWatch V, an Android-based smartphone with medical
sensors and apps that uses a cloud-based service platform. For additional
information, please visit www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is available at

http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are forward-
looking statements. The words "believe," "may," "will," "estimate," "continue,"
"anticipate," "intend," "expect" and similar expressions are intended to
identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT
CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES
FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY
SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN
ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD
OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION
UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
UNITED STATES SECURITIES LAWS.  ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN
THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED
FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS
OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/E2sWCuEm
http://resources.euroadhoc.com/us/1Vsl1JqX
http://resources.euroadhoc.com/us/xjnZF0tD
http://resources.euroadhoc.com/us/pfwE96bs

Further inquiry note:
Sensus Communication Consultants, Zürich:
Tel +41 43 366 55 11
Fax +41 43 366 55 12
Email  lifewatch@sensus.ch

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/E2sWCuEm
http://resources.euroadhoc.com/us/1Vsl1JqX
http://resources.euroadhoc.com/us/xjnZF0tD
http://resources.euroadhoc.com/us/pfwE96bs


issuer:      LifeWatch AG
             Rundbuckstrasse 6
             CH-8212 Neuhausen am Rheinfall
phone:       +41 52 632 00 50
FAX:         +41 52 632 00 51
mail:         users@lifewatch.com
WWW:      www.lifewatch.com
sector:      Healthcare Providers
ISIN:        CH0012815459
indexes:     SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
             SIX Swiss Exchange 
language:   English

Plus de actualités: LifeWatch AG
Plus de actualités: LifeWatch AG